Articles tagged with Drug Discovery
A study published in the Journal of Consumer Psychology found that consumers are more likely to engage in dishonest behavior, such as shoplifting or piracy, if they perceive a company as harming the environment or people. This effect occurs even when consumers have not personally had a bad experience with the company.
A new technique, ligand-accelerated non-directed C-H functionalization, enables the late-stage modification of complex drug molecules to improve therapeutic properties. Researchers used a special ligand molecule called 2-pyridone to enhance palladium's reactivity with targeted C-H bonds.
Scientists at the University of Edinburgh have identified two molecules, SMAD2 and SMAD3, that enhance cellular reprogramming efficiency. This breakthrough could accelerate production of induced pluripotent stem cells for studying diseases like multiple sclerosis and Parkinson's disease.
Researchers from Insilico Medicine and BitFury Group present a blockchain-based life data interchange system to decentralize and accelerate biomedical research. The system utilizes deep learning technologies to analyze human life data, reducing biases and democratizing healthcare access.
Researchers have discovered that glatiramer acetate, a widely used multiple sclerosis treatment, can also effectively kill certain multi-resistant bacteria. This breakthrough opens up new possibilities for treating cystic fibrosis patients and may even provide insight into the underlying causes of multiple sclerosis.
A new study by Sanford Burnham Prebys Medical Discovery Institute found that chloroquine, an anti-malarial drug, reduces the transmission of Zika virus from mother to fetus. The research suggests that chloroquine may be effective in treating and preventing Zika infections.
Anita Mattson's research focuses on naturally occurring molecules known as dimeric chromanones, which have high biological activity and may become powerful dual-action treatments for drug-resistant cancers. Her goal is to develop a new class of catalysts using silanediols to control the synthesis of these compounds.
A new model proposes returning control over human life data to patients, accelerating biomedical research through a secure and transparent distributed personal data marketplace utilizing blockchain and deep learning technologies. This approach can resolve challenges faced by regulators and improve patient satisfaction.
A new technique using blue LED lights and catalysts reduces the time to create radioactive molecules from months to hours, accelerating the arrival of new drugs to the marketplace. This innovation has the potential to bring medicines to patients much faster than before.
Insilico Medicine showcases its use of artificial intelligence to identify disease targets, generate molecular structures, and track interventions for metabesity. The company aims to prevent metabolic-rooted disorders such as diabetes and dementia.
A new $1.85 million grant will support a Phase 2 clinical trial of AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid, to test its effectiveness in slowing or stopping brain cell death in people with mild cognitive impairment or Alzheimer's disease.
A new combination therapy using registered drugs albendazole and antibiotics has dramatically shortened treatment time for lymphatic filariasis and onchocerciasis, reducing it from weeks to just seven days. This breakthrough could accelerate elimination of these debilitating diseases, prioritized by the UN's Sustainable Development Goals.
Researchers at Rutgers University have identified a protein complex called TldD that activates the antibiotic microcin B17 by removing its protective coating. This discovery could lead to the development of new antibacterial agents and drugs to combat toxins.
A new AI model called druGAN enables the generation of novel molecules with desired properties, surpassing previous GAN-based approaches. The model uses reinforcement learning to generate effective molecular graphs, paving the way for improved pharmaceuticals.
Researchers demonstrate an engineering approach to combine four drugs and control parasitic worms, a major breakthrough in treating nematode infections. The technique, developed by Chih-Ming Ho, uses a feedback system to quickly identify potent drug combinations that are effective on a small-animal model organism.
Researchers studied HIV drug combinations to understand why some drugs act synergistically while others do not. They found that virus protein mutations and host cell receptor density affect synergy, highlighting the need for personalized treatment approaches.
Scientists have developed a new sensor that can detect minute concentrations of methamphetamine and amphetamine in urine, allowing for real-time drug screening. The sensor uses a pumpkin-shaped molecule to bind with the drugs, triggering an electrical signal that appears on a smartphone screen.
The Children's Tumor Foundation and PLOS ONE are collaborating on a new funding program in neurofibromatosis (NF) research, integrating the Registered Reports model to enhance rigor, reproducibility, and transparency. The partnership aims to accelerate transparent science and eliminate publication bias.
Researchers at Dartmouth College developed a technique to produce synthetic steroids, paving the way for new drug discoveries. The process reduces time and expense to develop therapeutics from rare, mirror-image isomers of naturally occurring steroid structures.
The article presents a series of grid-based computational technologies for in silico virtual screening and molecular design of new drugs. The technologies use original CoMIn software to analyze molecular structure in terms of intermolecular interactions potentials and quantum functions.
A study by the European Center of Pharmaceutical Medicine at the University of Basel compared regulatory requirements for new drugs across 12 countries, revealing significant variations. Harmonization could improve efficiency and reduce prices, making innovative drugs available faster.
Researchers used baker's yeast to test natural compounds from soil-based bacteria, discovering diverse agents affecting various cell processes. These compounds may be used to treat conditions like Alzheimer's, Parkinson's, and cancer.
Researchers at the University of Sheffield have discovered that methotrexate, an arthritis drug, shows promise in treating Polycythemia Vera, a type of blood cancer affecting 3,000 people annually. The treatment has been shown to suppress JAK/STAT pathway activation and normalise blood counts in mice models.
Researchers have discovered a potential new treatment for delayed neuropathy caused by insecticides or chemical exposure. The study identified the TRPA1 channel as responsible for the condition and found that duloxetine and ketotifen alleviate symptoms in animal models.
Researchers at Binghamton University have developed a new drug that demonstrates superior anti-parkinsonian efficacy over current medications. The compound, D-512, provides longer symptom relief and prolongs the time window in which benefits are shown.
A new method developed by an international research team uses yeast cells to speed up drug discovery by linking compounds to cellular processes they target. The study found that natural compounds derived from soil microbes hold promise as potential medicines against various diseases, including infections and cancer.
Researchers at the University of Wisconsin-Madison have developed an automated screening test to create all-chemical replacements for traditional stem cell growth materials. This innovation enables wider use of stem cells in regenerative medicine, drug discovery, and testing environmental chemicals for vascular toxicity.
Griffith University researchers used Australia's fastest camera to measure the time it takes for molecules to break apart, achieving a record-breaking 15 millionth of a billionth of a second. This breakthrough could help design new molecules for materials science and drug discovery.
Scientists have developed a systematic approach to screen for molecules produced by molds, finding 17 new natural products in three species. The technology, called FAC-MS, uses genomics and data analytics to identify gene clusters that produce valuable chemicals.
Researchers from Novartis and collaborators have discovered a novel drug candidate, KDU731, to combat the protozoan parasite Cryptosporidium, which causes cryptosporidiosis. This breakthrough offers hope for new treatment options against this disease, which currently has no effective treatments or vaccines.
Researchers have developed a new approach to create integration-free, Myc- and Lin28-free human induced pluripotent stem cells. This breakthrough method reduces the neoplastic risk associated with IPSC generation, enabling their utility in regenerative medicine and personalized medicine.
The Biogerontology Research Foundation will present its work on applying artificial intelligence and deep learning to combat aging and age-related disease. The foundation has published seminal papers demonstrating the potential of these approaches to accelerate drug discovery and development, reducing costs and risks.
The Biogerontology Research Foundation is helping to develop artificial intelligence for accelerated drug discovery in aging and age-related diseases. Researchers have made significant progress in using deep learning-based approaches to characterize biomarkers of ageing and predict the chronological age of patients.
Insilico Medicine will showcase its pioneering work in applying deep learning techniques to drug discovery, biomarker development, and aging research. The company's presentation highlights the applications of Generative Adversarial Networks (GANs) in oncology and infectious diseases.
A new compound, MMV390048, has been discovered and shown to be effective against resistant strains of the malaria parasite across its entire lifecycle. The research holds great promise for a single-dose cure, potentially contributing to the eradication of malaria.
Researchers have created a technique to encase proteins in silica cages, keeping them intact at high temperatures up to 100°C. This method, called ensilication, has the potential to revolutionize vaccine storage and transportation, particularly for remote or resource-constrained areas.
Researchers discovered new structural details of an angiotensin II receptor called AT2, which could be a target for new medicines. The information uncovered could give drug developers a new path for compounds that combat pain and inflammation or promote tissue regeneration.
Scientists have discovered a synergistic effect between an anticancer and an antirheumatic drug, improving the former's ability to kill off cancer cells. The combination works by interacting with the cell's DNA, disrupting normal function and causing cell death.
A team of scientists from Kyoto University has developed a simpler approach to drug discovery using decision trees, achieving high predictive ability with reduced data sets. The new method could lead to significant cost savings in the drug development process.
Researchers have created a precise atomic map of the frontline antimalarial drug mefloquine, showing how its structure could be changed to make it more effective. The study provides a route to develop new treatments with fewer resources and potentially reduced side effects.
Scientists discovered that resveratrol preserves neuromuscular synapses and muscle fibers in aging mice, mirroring the effects of a low-calorie diet and exercise. Metformin also showed neuroprotective qualities, slowing muscle fiber aging without affecting neuromuscular junctions.
A Penn study found that a high-fat diet causes epigenetic changes in fat cells, leading to obesity and type 2 diabetes. The research also identified a genetic defect in the Ucp1 gene that contributes to obesity, which can be overcome with treatment.
McMaster researchers have discovered a new combination therapy that effectively treats the world's worst infectious diseases, including superbugs resistant to all known antibiotics. The treatment targets Gram-negative bacteria with an intrinsically impenetrable outer shell, making infections deadly in hospital settings.
Researchers at Georgia Institute of Technology have developed triboelectric nanogenerators to charge molecules in mass spectrometers, dramatically boosting sensitivity and allowing for smaller sample volumes. The technology enables controlled ionization and eliminates waste, opening new avenues for scientific applications.
Researchers have discovered a new way to identify and test new drugs using differential mobility spectrometry (DMS), which analyzes drug molecules based on their response to an electrical field. This technique can measure drug properties in seconds, allowing for high-throughput testing of hundreds or thousands of drugs.
Researchers have identified B0AT1 inhibitors as a potential replacement for gastric bypass surgery in treating obesity and related disorders. These compounds, including benztropine, could replicate the effects of gastric bypass by reducing nutrient absorption, offering a new treatment option.
A Virginia Tech research team has received a $431,126 NIH grant to improve the malaria compound MMV008138. The team aims to create more potent versions of the drug targeting the parasite's ability to produce isopentenyl pyrophosphate.
The Harrington Discovery Institute has selected three 2016 partnership scholars to support groundbreaking research in Alzheimer's disease and blindness. The scholars will receive funding and expert pharmaceutical guidance to advance their discoveries into new medicines.
Researchers at Michigan State University have discovered a chemical compound that can stop the spread of melanoma cells by up to 90 percent. The compound targets a gene's ability to produce RNA molecules and proteins in melanoma tumors, effectively shutting down the disease's progression.
A team of Vanderbilt researchers has cleared a major hurdle in their quest to develop an Alzheimer's treatment, with the FDA approving its first human trial. The investigational drug aims to target major pathologies of the disease and selectively activate a key receptor in the brain.
Scientists at InSilico Medicine developed a proof-of-concept AI model using Generative Adversarial Autoencoders (AAEs) to generate molecular fingerprints of cancer-killing molecules. The study demonstrates the potential for AI to accelerate pharmaceutical R&D and improve clinical trial success rates.
Researchers developed an efficient process to rapidly discover new 'enediyne natural products' from soil microbes that could be further developed into extremely potent anticancer drugs. The study highlights microbial natural products as abundant sources of new drug leads, saving time and resources compared to traditional approaches.
Researchers discovered that two M1-selective medications reversed memory deficits and extended the lifespan of mice with neurodegenerative disease. The findings support the concept that more specific drugs can be effective in treating cognitive symptoms.
A team of researchers has identified a network of genes in the brain that contribute to epilepsy, and predicts that a known anti-epileptic drug can restore its function. The study's 'network-biology' approach may provide a faster and cheaper way to discover new treatments.
A new study reveals that diabetes drugs' weight loss effects are controlled by multiple brain regions, excluding the hypothalamus. Researchers hope to develop more effective treatments for obesity by understanding how these drugs work in the brain.
IUPUI chemists have developed a new molecular binding technique that can shorten or abridge the human and animal drug discovery and development process. The new method, which uses site-selective C-H arylation of primary aliphatic amines, has potential benefits for both the pharmaceutical industry and patients.
Researchers discover over 31,000 repurposable drug candidates for various diseases, including Parkinson's and tuberculosis. The study uses computational methods to identify shared properties between genes, drugs, and diseases, promising a more efficient and cost-effective approach to pharmaceutical discoveries.
Researchers found a genetic alteration in the DIXDC1 gene that affects brain cell growth and communication in individuals with autism spectrum disorders. This discovery holds promise for identifying new medications targeting core symptoms of autism.
A newly identified protein, NTR2, has been discovered that activates drugs like delamanid against leishmaniasis. This finding holds promise for developing more effective treatments for the disease.
IDRI's TB Discovery Program will focus on developing more effective, cheaper, and faster-acting drugs to combat multi-drug resistant TB strains. The new funding from Eli Lilly will support the screening of over 500,000 compounds in search of potential TB drugs.